Related Experiment Video
Updated: Oct 12, 2025

Author Spotlight: Advancements in Refractive Surgical Correction for Presbyopia and Exploring Postoperative Visual Acuity
Published on: September 20, 2024
Mitomycin C application after photorefractive keratectomy in high, moderate, or low myopia: Systematic review and
Yassamine Ouerdane1, Mohamed Sayed Zaazouee2, Moaiad Eldin Ahmed Mohamed3
1Faculty of Medicine, Saad Dahlab University, Blida, Algeria; International Medical Research Association (IMedRA), Egypt.
Abstract:
Photorefractive keratectomy (PRK) is considered a safe approach laser procedure with a clinical significance in correcting myopia results. PRK requires removing the whole superficial epithelium. The integrity of the epithelial basement membrane and the deposition of abnormal extracellular matrix can put the cornea in a probable situation for corneal haze formation. Mitomycin C (MMC) is applied after excimer laser ablation as a primary modulator for wound healing, limiting corneal haze formation. We aim to summarize the outcomes of MMC application after laser ablation. We searched Scopus, PubMed, Cochrane CENTRAL, and Web of Science till December 2020 using relevant keywords. The data were extracted and pooled as mean difference (MD) or risk ratio (RR) with a 95% confidence interval (CI), using Review Manager software (version 5.4). Our analysis demonstrated a statistically significant result for MMC application over the control group in terms of corneal haze formation postoperatively (RR = 0.29, 95% CI: [0.19, 0.45], P < 0.00001). Regarding corrected distance visual acuity (CDVA), no significant difference was observed between the MMC group and the control group (MD = 0.02; 95% CI: [-0.04, 0.07]; P = 0.56). Regarding the uncorrected distance visual acuity (UDVA), the analysis favored the MMC application with (MD -0.03, 95% CI: [-0.06, -0.00]; P = 0.05). There was no statistically significant increase in complications with MMC. In conclusion, MMC application after PRK is associated with a lower incidence of corneal haze formation with no statistically significant side effects. The long term effect can show improvement regarding UDVA favoring MMC. However, there is no significant effect of MMCs application regarding CDVA, and SE.
Insights
Mitomycin C (MMC) application after photorefractive keratectomy (PRK) significantly reduces corneal haze formation. This study found no significant impact on corrected distance visual acuity but suggested potential long-term improvements in uncorrected distance visual acuity with MMC.
Area of Science:
- Ophthalmology
- Corneal Surgery
- Laser Vision Correction
Background:
- Photorefractive keratectomy (PRK) is a common laser procedure for myopia correction.
- Epithelial removal during PRK can lead to corneal haze formation.
- Mitomycin C (MMC) is used to modulate wound healing and prevent haze.
Purpose of the Study:
- To summarize the outcomes of applying Mitomycin C (MMC) after excimer laser ablation in PRK.
- To evaluate the effect of MMC on corneal haze, visual acuity, and complications.
Main Methods:
- Systematic review of studies from Scopus, PubMed, Cochrane CENTRAL, and Web of Science up to December 2020.
- Data extraction and pooling using Review Manager software.
- Analysis of corneal haze formation, corrected distance visual acuity (CDVA), and uncorrected distance visual acuity (UDVA).
Main Results:
- MMC application significantly reduced postoperative corneal haze (RR = 0.29, P < 0.00001).
- No significant difference in CDVA was observed between MMC and control groups (MD = 0.02, P = 0.56).
- UDVA favored MMC application (MD -0.03, P = 0.05), with no significant increase in complications.
Conclusions:
- MMC application after PRK is associated with a lower incidence of corneal haze.
- No statistically significant side effects were observed with MMC use.
- Long-term effects may include improved UDVA, but CDVA and spherical equivalent (SE) are not significantly affected.
More Related Videos
Related Concept Videos
Angle Closure Glaucoma: Treatment
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...

